Shuzhong Cui

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A Multifunctional Cascade Bioreactor Based on Hollow‐Structured Cu₂MoS₄ for Synergetic Cancer Chemo‐Dynamic Therapy/Starvation Therapy/Phototherapy/Immunotherapy with Remarkably Enhanced Efficacy

Mengyu Chang, Man Wang, Meifang Wang et al. · Advanced Materials · 2019 · 484 citations

Medicine, Bioengineering, Oncology +17

LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway

Xianzi Yang, Tiantian Cheng, Qingjun He et al. · Molecular Cancer · 2018 · 406 citations · Full text

Medicine, Cancer Biology, Oncology +17

Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer

Yadong Xie, Yifan Zhao, Lei Shi et al. · Journal of Clinical Investigation · 2020 · 207 citations · Full text

Life Sciences, Immunology, Pathobiology +17

An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity

Shengwei Jiang, Haoran Zhao, Weijie Zhang et al. · Cell Reports Medicine · 2020 · 180 citations · Full text

Engineering, Bioengineering, Biomedical Engineering +17